Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?

Things aren't getting much better for Pfizer (PFE -1.29%). The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years. And although Pfizer's revenue is growing again, that's not enough for the drugmaker to get back in the good graces of investors. Pfizer has, unquestionably, made progress. Many new approvals and acquisitions have expanded its lineup and pipeline. However, it's fair to ...